Botulinum toxin A (BTX-A) injections to the salivary glands are effective in the treatment of drooling, and complications are rare. However, there are only a few previous reports on the long-term use of BTX-A injections. This study retrospectively analyzes our experience of treating drooling with repeated BTX-A injections in patients with neurodegenerative diseases. All patients who received repeated BTX-A injections to the submandibular glands at Tampere University Hospital in 2004-2013 were included in the analysis. Six patients, aged from 6 to 21 years, were included in the study, and a total of 41 bilateral BTX-A injections were administered to their submandibular glands. The average number of injections per patient was 6 (range: 3-11). The average interval between the injections was 9.8 months (range: 4-18), and 95% (39/41) of the injections were performed with good response. The complication rate of the BTX-A injections was 2.4% (1/41), since one of the patients had swallowing problems after an injection. BTX-A injections to the submandibular glands are effective and have a low morbidity rate, and repeated injections can be recommended as long-term treatment of drooling.

Johnson H, Scott A: A Practical Approach to Saliva Control. Tucson, Communication Skill Builders Inc., 1993.
Blasco PA, Allaire JH; participants of the Consortium on Drooling: Drooling in the developmentally disabled: management practices and recommendations. Dev Med Child Neurol 1992;34:849-862.
Tahmassebi JF, Curzon ME: The cause of drooling in children with cerebral palsy - hypersalivation or swallowing defect. Int J Paediatr Dent 2003;13:106-111.
Garret JR: The proper role of nerves in salivary secretion. J Dent Res 1987;66:387-397.
Hussein I, Kershaw A.E, Tahmassebi JF, Fayle SA: The management of drooling in children and patients with mental and physical disabilities: a literature review. Int J Paediatr Dent 1998;8:3-11.
Jongerius PH, Rotteveel JJ, van den Hoogen F, Joosten F, van Hulst K, Gabreels FJM: Botulinum toxin A: a new option for treatment of drooling in children with cerebral palsy. Presentation of a case series. Eur J Pediatr 2001;160:509-512.
Dolly JO, Ashton AC, Mclnnes C, Wadswort JDF, Poulain B, Tauc L, Shone CC, Melling J: Clues to the multi-phasic inhibitory action of botulinum neurotoxin on release of transmitters. J Physiol 1990;3:237-246.
Borodic GE, Ferrante R: Effects of repeated botulinum toxin injections on orbicularis oculi muscle. J Clin Neuroophthalmol 1992;12:121-127.
Jongerius PH, Rotteveel JJ, van Limbeek J, Gabreels FJM, van Hulst K, van den Hoogen FJ: Botulinum toxin effect on salivary flow rate in children with cerebral palsy. Neurology 2004;63:1371-1375.
Banerjee KJ, Glasson C, O'Flaherty SJ: Parotid and submandibular botulinum toxin A injections for sialorrhoea in children with cerebral palsy. Dev Med Child Neurol 2006;48:883-887.
Reddihough D, Erasmus CE, Johnson H, McKellar MW, Jongerius PH: Botulinum toxin assessment, intervention and aftercare for paediatric and adult drooling: international consensus statement. Eur J Neurol 2010;17 Suppl 2:109-121.
Montgomery S. McCusker S, Hendry J, Lumley E, Kubba H: Botulinum toxin A for children with salivary control problems. Int J Ped Otorhinol 2014;78:1970-1973.
Erasmus CE, Van Hulst K, Van Den Hoogen FJ, Van Limbeek J, Roeleveld N, Veerman EC, Rotteveel JJ, Jongerius PH: Thickened saliva after effective management of drooling with botulinum toxin A. Dev Med Child Neurol 2010;52:e114-e118.
Basciani M, di Rienzo F, Fontana A, Copetti M, Pellegrini F, Intiso D: Botulinum toxin type B for sialorrhoea in children with cerebral palsy: a randomized trial comparing three doses. Dev Med Child Neurol 2011;53:559-564.
Jongerius PH, Joosten F, Hoogen FJA, Gabreels FJM, Rotteveel JJ: The treatment of drooling by ultrasound-quided intraglandular injections of botulinum toxin type A into the salivary glands. Laryngoscope 2003;113:107-111.
Jost WH: Treatment of drooling in Parkinson's disease with botulinum toxin. Mov Disord 1999;14:1057.
Ellies M, Gottstein U, Rohrbach-Volland MD, Arglebe C, Laskawi R: Reduction of salivary flow with botulinum toxin: extended report on 33 patients with drooling, salivary fistulas and sialadenitis. Laryngoscope 2004;114:1856-1860.
Berweck S, Schroeder AS, Lee SH, Bigalke H, Heinen F: Secondary non-response due to antibody formation in a child after three injections of botulinum toxin B into the salivary glands. Dev Med Child Neurol 2007;49:62-64.
Brei TJ: Management of drooling. Semin Pediatr Neurol 2003;10:265-270.
Jongerius PH, Van Den Hoogen FJ, Van Limbeek J, Gabreels FJ, Van Hulst K, Rotteveel JJ: Effect of botulinum toxin in the treatment of drooling, a controlled clinical trial. Pediatrics 2004;114:620-627.
Bachrach SJ, Walter RS, Trzcinski K: Use of glycopyrrolate and other anticholinercic medications for sialorrhea in children with cerebral palsy. Clin Pediatr 1998;37:485-490.
Formeister E, Dahl J, Rose A: Surgical management of chronic sialorrhea in pediatric patients: 10-year experience from one tertiary care institution. Int J Ped Otorinol 2014;78:1387-1392.
Smith WP, Peters WJ, Markus AF: Submandibular gland surgery: an audit of clinical findings, pathology, and postoperative morbidity. Ann R Coll Surg Engl 1993;75:164-167.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.